24/7 Wall St. » Search Results » SNSS

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

Jon C. Ogg — Fri, 18 May 2012 11:47:56 +0000

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take place from June 1 to June 5 in Chicago. This has been a make or break event for many cancer treatment and identification efforts. Some of the exhibitors being featured by ASCO are Dendreon, Eli Lilly & Co. (NYSE: LLY), Genentech, Helsinn, Eisai, and Montefiore/Einstein.

24/7 Wall St. has compiled a log of companies which have already signaled in press releases that they will be presenting data or that data will be presented on their behalf at the 2012 ASCO Annual Meeting. We have previewed more than 25 companies so far and that is not even including Big Pharma names. As of May 18, the total abstracts submitted were 5,264 and of those there have been 2,744 which have been accepted for presentation at ASCO. Of those accepted for presentation, some 1,859 are going to be ‘ePublication only’ for viewers. The breakdown for the Abstracts shows that the oral presentation is currently 257 presentations and 2,487 are listed as poster presentation only.

The most presentations accepted (203) so far are focused on Genitourinary Cancer, which covers urinary tract and male genital tract as follows: Prostate cancer; Bladder cancer; Kidney cancer; Testicular cancer; Penile cancer; Nonmalignant tumors of the urinary tract and male reproductive system; and Von Hippel Lindau disease. As of today, the fewest accepted presentations (93) cover Pediatric oncology.

Amgen Inc. (NASDAQ: AMGN), the largest independent biotech that there is, recently showed updated results from a Phase 2 study showing that treatment with blinatumomab helped achieve a high-rate of complete response in 72% of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated in the study. This blinatumomab is the first of a new class of agents called bi-specific T cell engagers antibodies, which are designed to harness the body’s cell-destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas, such as ALL. Full results of the study will be presented during an oral abstract session on June 4 at the ASCO Annual Meeting.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) recently sold off but will will have updated clinical data from the pivotal PACE trial of ponatinib, its investigational pan-BCR-ABL inhibitor in patients with chronic myeloid leukemia (CML) on June 4. The company said that the data will form the basis of its regulatory filings for marketing approval of Ponatinib for patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblasatic leukemia.

ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo, Co., Ltd. (Japan) will have an oral presentation at the ASCO Annual Meeting featuring Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma. ArQule announced that this randomized, double-blind study met its primary endpoint in January and will now present the full results from this trial, including positive data in the pre-defined c-MET high population. Additional clinical data with tivantinib will be featured in two poster discussions and two general poster sessions.

Array BioPharma Inc. (NASDAQ: ARRY) has recently risen on its lung cancer and melanoma results. The company has three oral presentations at the annual meeting after having already presented Phase 1 data on MEK162 in 28 patients with biliary tract cancer at the ASCO Gastrointestinal Cancers Symposium in January 2012 showing that it was well tolerated and showed evidence of clinical efficacy in this patient population, including a complete response and a partial response. Stable disease was observed in 12 patients. The company has licensed selumetinib to AstraZeneca (NYSE: AZN) and licensed MEK162 to Novartis (NYSE: NVS).

Filed under: Active Trader, Biotech, Calendar, Cult Stock, Drug companies, Editor's Picks, Healthcare, Medical Tagged: ABPI, AMGN, ARIA, ARQL, ARRY, AVEO, BMY, BVTI, CLDX, CYCC, CYTR, DNDN, EXEL, GALE, GHDX, GNBT, IMGN, LLY, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA

Top Day Trader Alerts (DNDN, CIEN, DEER, SNSS, CBK)

Douglas A. McIntyre — Fri, 11 Dec 2009 13:38:20 +0000

These are this morning’s top day trader and active trader alert stocks. There is much more detailed analysis and data on each stock story via a link to VSInvestor.com:

Dendreon Corporation (NASDAQ: DNDN) is down only 1% on this discounted secondary offering.

CIENA Corporation (NASDAQ: CIEN) is trying to find a bottom with a gain after yesterday’s lows matched previous lows seen.

Deer Consumer Products, Inc. (NASDAQ: DEER) is today’s top day trader alert… huge discount on secondary offering for the appliances maker in China.

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) is continuing yesterday’s run so far after doubling.

Christopher & Banks Corp. (NYSE: CBK) is up 16% and appears to be the top gainer for NYSE stocks this morning.

You can join our open email distribution list to hear more news on key analyst calls, top day trader alerts, mergers and acquisitions, Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

Jon C. Ogg

Posted in Active Trader, Pre-Market Activity, Trading Alert Tagged: CBK, CIEN, DEER, DNDN, SNSS

Top Pre-Market Analyst Upgrades (ALK, AMR, AAPL, CAL, DAL, DELL, JPM, LDK, PENN, SCR, SNSS, LCC)

Douglas A. McIntyre — Tue, 12 Aug 2008 06:23:22 +0000

These are some of the top analyst upgrades and positive calls we are seeing this Tuesday morning:

Alaska Air (ALK) Raised to Overweight at JPMorgan.
AMR Corp. (AMR) Raised to Overweight at JPMorgan.
Apple (AAPL) Started as Outperform at Credit Suisse; reiterated Overweight at Lehman.
Continental Air (CAL) Raised to Overweight at JPMorgan.
Delta Air (DAL) Raised to Overweight at JPMorgan.
Dell (DELL) Started as Outperform at Credit Suisse.
JPMorgan Chase (JPM) Started as Outperform at Bernstein.
LDK Solar (LDK) Raised to Neutral at Piper Jaffray.
Penn National Gaming (PENN) Raised to Overweight at JPMorgan.
Simcere Pharmaceutical Group. (SCR) Started as Buy at Goldman Sachs.
Sunesis Pharmaceuticals Inc. (SNSS) Started as Buy at Piper Jaffray.
US Airways (LCC) Raised to Overweight at JPMorgan.

Jon C. Ogg
August 12, 2008

Today’s Market Winners and Losers

247sam — Tue, 11 Sep 2012 15:08:14 +0000

The stock market is up Friday, with the Dow Jones Industrial Average up 0.65%, the Nasdaq up 0.32% and the S&P 500 up 0.47%. The biggest winners today include a pharmaceutical company with strong clinical trial results and an investment firm getting rid of delinquent loans. The biggest loser is offering $100 million in senior notes to the public.

Here are Tuesday’s market winners and loser.

Biggest Winners

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) are up 31.82% to $3.48 on trading volume of 5.5 million shares. The company on Tuesday reported strong results for its Phase 3 trial vosaroxin, a drug intended for patients with lukemia. The 52-week high is $3.57.

Shares of MGIC Investment Corp. (NYSE: MTG) are up 10.25% to $1.78 on trading volume of 5.6 million shares. The firm announced it had ended primary deliquent inventory of 150,388 loans. The 52-week high is $5.15.

Biggest Loser

Shares of Sequenon Inc. (NASDAQ: SQNM) are down 9.91% to $3.52 on trading volume of 2.7 million. The company announced a proposed offering of $100 million of convertible senior notes. The 52-week low is $2.65.

Samuel Weigley

Follow him on Twitter: SWeigley

Filed under: 24/7 Wall St. Wire Tagged: MTG, SNSS, SQNM

Holiday Sales Forecasts Worsen

Douglas A. McIntyre — Thu, 20 Oct 2011 10:15:11 +0000

The Nation Retail Federation expects holiday sales to rise 2.8% to $466 billion this year. That estimate has already been questioned as unemployment stays above 9% and discretionary income remains stagnant. Another indication that this holiday may be nearly disastrous is a new Gallup poll.

According to the research firm, “Americans forecast they will spend $712 on Christmas gifts this year, nearly identical to the $715 they estimated they would spend on Christmas at this time last year.” Holiday sales in 2008 were supposed to be the lowest in years, but Christmas expenditures were $801 that year and $740 in 2009, based on Gallup data.

The Wall Street Journal recently reported that many small retailers are concerned that troubled holiday revenue could push them out of business. A by-product of this would be a weak economy in the first quarter of 2012 as retailers cut staff and close stores because they did not do well in November and December. Job cuts cause higher unemployment, which further undermines national retail sales. This happened in 2008 and 2009. That pattern appears to be one that will be repeated this year as well.

Whatever stimulus packages or jobs programs may come out of Washington are already too late to bolster the economy until the first or perhaps second quarter of 2012. That assumes any bill to help the jobs market will be passed at all.

It is too late in the year to reverse the move into another period of dismal holiday sales. The work to remedy the problem needed to be done much earlier this year. The Nation Retail Federation’s forecasts are too optimistic. Many of its members are in for a hard time.

Methodology: Results for this Gallup poll are based on telephone interviews conducted Oct. 6 to 9, 2011, with a random sample of 1,005 adults, aged 18 and older, living in all 50 U.S. states and the District of Columbia.

Douglas A. McIntyre

Filed under: Retail

Best BioHealth Stocks of 2010, Outlook for 2011 (JAZZ, DNDN, HGSI, ARIA, AMRN, NBIX, THRX)

Jon C. Ogg — Tue, 30 Nov 2010 16:32:30 +0000

2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009. In 2009, companies like Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Dendreon Corp. (NASDAQ: DNDN), and Human Genome Sciences, Inc. (NASDAQ: HGSI) led the 2009 pack with exponential returns that were 500% and higher. At BioHealthInvestor.com, we have tracked many of the exponential winners for 2010 with outlooks into 2011. Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is our sole repeat performer in 2010. Others include ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Amarin Corporation plc (NASDAQ: AMRN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Theravance Inc. (NASDAQ: THRX).

Many companies were screened out because performance has faltered or because of limited history. Read the full lists below at BioHealthInvestor.com:

Outlook 2011: ARIA, CHTP, CYCC, ENMD, EXAS, EXEL, FOLD, IDIX
Outlook 2011, Part II: AMRN, ILMN, INHX, JAZZ, NBIX, NPSP, THRX, VPHM

Stocks covered above in detail at BioHealthInvestor.com are ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), EntreMed Inc. (NASDAQ: ENMD), Exact Sciences Corporation (NASDAQ: EXAS), Exelixis, Inc. (NASDAQ: EXEL), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Amarin Corporation plc (NASDAQ: AMRN), Illumina Inc. (NASDAQ: ILMN), Inhibitex Inc. (NASDAQ: INHX), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Neurocrine Biosciences Inc. (NASDAQ: NBIX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM).

You can also see the same sort of search from 2009 for the 2010 outlook that was done at BioHealthInvestor.com.

JON C. OGG

Filed under: Analyst Calls, Biotech, Drug companies, FDA, Healthcare, Medical Tagged: AMRN, ARIA, DNDN, HGSI, JAZZ, NBIX, THRX

DJIA 2010: Best Targets Imply 11,455 (BAC, CVX, CSCO, GE, HPQ, INTC, JPM, KFT, PFE, PG, TRV, WMT, XOM, AA, BA, DIA)

Douglas A. McIntyre — Mon, 04 Jan 2010 11:59:57 +0000

We have started taking a look at the 30 stocks comprising the Dow Jones Industrial Average to see which stocks had the most implied upside of all DJIA components. We have taken a snapshot of the “mean price target” of each of the 30 DJIA components based upon Thomson Reuters consensus price targets for a year out. This list is expanded beyond just the ten with the most upside because there were more than 10 components with expected double-digit returns and because the list was also dominated by financial and energy stocks. The list of double-digit performance expectations is as follows: Bank of America Corporation (NYSE: BAC), Chevron Corp. (NYSE: CVX), Cisco Corporation (NASDAQ: CSCO), General Electric Co. (NYSE: GE), Hewlett-Packard Co. (NYSE: HPQ), Intel Corporation (NASDAQ: INTC), JPMorgan Chase & Co. (NYSE: JPM), Kraft Foods Inc. (NYSE: KFT), Pfizer Inc. (NYSE: PFE), Procter & Gamble Co. (NYSE: PG), The Travelers Companies, Inc. (NYSE: TRV), Wal-Mart Stores Inc. (NYSE: WMT), and Exxon Mobil Corp. (NYSE: XOM).

As you will sadly see, Alcoa, Inc. (NYSE: AA) and Boeing Co. (NYSE: BA) shares imply more downside than upside as those two stocks are the only DJIA components already trading above their implied one-year consensus mean price targets. We first looked at the Warren Buffett stocks last week with the most implied upside and decided to run the calculation on the 30 DJIA components for this week. The implied results show each ticker, the closing price for 2009, the mean price target from Thomson Reuters, the expected percentage price gain derived by the change in Friday’s price to the mean target, and we even included the 52-week trading range of each component. The results are as follows:

Ticker   Price   Target   Exp.Gain 52 Wk Range
AA   $16.12   $16.02   -0.6%   4.97 – 16.51
AXP   $40.52   $40.68   0.4%   9.71 – 42.25
BA $54.13   $52.76   -2.5%   29.05 – 56.56
BAC   $15.06   $21.11   40%   2.53 – 19.10
CAT   $56.99   $61.81   8.4%   21.71 – 61.28
CVX   $76.99   $85.80   11.4%   56.12 – 79.82
CSCO   $23.94   $27.18   13.5%   13.61 – 24.83
DD      $33.67   $35.17   4.4%   16.05 – 35.62
DIS   $32.25   $32.61   1.1%   15.14 – 32.75
GE      $15.13   $17.33   14.5%   5.87 – 17.52
HD   $28.93   $30.66   5.9%   17.49 – 29.44
HPQ   $51.51   $59.21   14.9%   25.39 – 52.95
IBM   $130.90   $136.05   3.9%   81.76 – 132.85
INTC $20.40   $24.04   17.8%   12.05 – 21.27
JNJ   $64.41   $66.80   3.7%   46.25 – 65.41
JPM   $41.67   $53.53   28.4%   14.96 – 47.47
KFT   $27.18   $31.90   17.3%   20.81 – 29.84
KO   $57.00   $62.38   9.4%   37.44 – 59.45
MCD   $62.44   $67.71   8.4%   50.44 – 64.75
MMM $82.67   $90.53   9.5%   40.87 – 84.32
MRK   $36.54   $39.28   7.5%   20.05 – 38.42
MSFT $30.48   $32.75   7.44%   14.87 – 31.50
PFE   $18.19   $20.37   12%   11.62 – 18.99
PG      $60.63   $67.19   10.8%   43.93 – 63.48
T $28.03   $29.96   6.8%   21.44 – 29.46
TRV   $49.86   $56.82   13.9%   33.07 – 54.47
UTX   $69.41   $76.06   9.5%   37.40 – 70.89
VZ      $33.13   $34.23   3.6%   26.10 – 34.76
WMT   $53.45   $60.09   12.4%   46.25 – 57.51
XOM   $68.19   $79.29   16.2%   61.86 – 82.73

We ran an average of the “mean price targets” to get an implied consensus upside for the DJIA in 2010. If we average out all of the components, then we end up with an average consensus expected gain of 10.3% for 2010. But then if we eliminate the two expected negative return components and remove the two major banks with an expected gain of 28% and 40% then our expected average gain per component is 9.4%.

We wanted to assign this for a fixed price on the DJIA for 2010, but there is just one problem here. The DJIA is a price-weighted index that cares not about market capitalization. The only matter is the share price of each stock, and almost all DJIA components pay a regular dividend and a stock split or a further index component change will change all of the component weightings. So to be fair, we have taken an average of the averages and assigned an average implied upside of 9.85% for all DJIA components. If this were to be uniform and were not distracted by companies with larger share prices moving up more or less than the lower priced stocks, then the closing price of $10,428.05 for 2009 would imply a DJIA price of approximately $11,455.21 for 2010. As for the DIAMONDS Trust (NYSE: DIA) this implies an upside target of roughly $114.32 for the same period and not taking any index/ETF price tracking changes into account.

We have already given some caveats here. First and foremost, if we used the formal price targets and new implied weightings and backed out dividend payments then we’d end up with a slightly different figure. More importantly, research departments go almost dark in the last two weeks of any given calender year and there are gaps of coverage updates at the end of the year. And that being said, price targets at major research firms often get updated throughout the first weeks of a new calendar year. So toward the end of January we would consider revisiting this to look for new implied targets. We did not include P/E ratios as we normally would since this is the same sort of screen which many value investors would use. The last caveat is also the most irritating one: analysts are fickle and wishy-washy when it comes to price targets, so all of these figures will vary with the direction of the stock market performance.

I would like to personally invite you to join in with the thousands of readers on our free daily email distribution list from 24/7 Wall St. to hear about ongoing day trader and options trader alerts, analyst upgrades and downgrades, stock and market rumors, Buffett and guru investor news, M&A and IPOs, and more.

JON C. OGG
January 4, 2010

Posted in Active Trader, Analyst Calls, Banking, Banking & Finance, Corporate Governance, Dividend, Dividends & Buybacks, Economy, Editor's Picks, ETF, ETFs & Mutual Funds, Financial Stocks, Index, Large Cap Stocks, Oil & Gas, Shareholder Issues, Trading Alert, Value Investing Tagged: AA, BA, BAC, CSCO, CVX, DIA, GE, HPQ, INTC, JPM, KFT, PFE, PG, TRV, WMT, XOM

Top 2010 Stock Picks from… Everyone (AAPL, GE, CMCSA, MRVL, BIDU, DRYS, POT, LVLT, C, CVX, HPQ, KBH)

Douglas A. McIntyre — Fri, 01 Jan 2010 11:59:56 +0000

2009 is over, for better or worse. Now it is time to look ahead. We wanted to look for the best top stock picks for 2010 from our partners and from key financial websites. We compiled all of these 2010 stock picks into grouped lists with links directly to each, but there was one standout issue here: Apple Inc. (NASDAQ: AAPL) and General Electric Co. (NYSE: GE) were hardly picked for 2010. Some of the more common and widely held names that came up as common 2010 stock picks were Comcast Corporation (NASDAQ: CMCSA), Marvell Technology Group Ltd. (NASDAQ: MRVL), Baidu, Inc. (NASDAQ: BIDU), DryShips, Inc. (NASDAQ: DRYS), Potash Corp. of Saskatchewan (NYSE: POT), Level 3 Communications Inc. (NASDAQ: LVLT), Citigroup Inc. (NYSE: C), Chevron Corp. (NYSE: CVX), Hewlett-Packard Company (NYSE: HPQ), and KB Home (NYSE: KBH). There are literally dozens of other stock picks in 2010′s top stock picks.

We have links to the top 2010 stock picks from InvestorPlace.com, TheStreet.com, DailyFinance.com, BloggingStocks.com, MarketWatch, Fortune, Smart Money, MorningStar, and even from our own picks for 2010 and some potential 10-bagger Biotech stocks at BioHealthInvestor.com. In this we have only provided the stock names, and price targets, expectations, and every other detail is in the link at each grouping.

BioHealthInvestor.com “Potential 10-Bagger Biotechs for 2010″

InvestorPlace.com “How to Make Money in 2010″

Sourcefire, Inc. (NASDAQ: FIRE)
Marvell Technology Group (NASDAQ: MRVL)
Hi-Tech Pharmacal (NASDAQ: HITK)
Baidu Inc. (NASDAQ: BIDU)
Dril-Quip, Inc. (NYSE: DRQ)

InvestorPlace.com “5 Great Retail Stocks for 2010″

Abercrombie & Fitch Co. (NYSE: ANF)
Chico’s FAS Inc. (NYSE: CHS)
Guess? Inc. (NYSE: GES)
Jos. A. Bank Clothiers (NASDAQ: JOSB)
Nordstrom Inc. (NYSE: JWN)

InvestorPlace.com “Trends from China for 2010″

Duoyuan Global Water Inc. (NYSE: DGW)
Xinyuan Real Estate (NYSE: XIN)
Baidu, Inc. (NASDAQ: BIDU)
Ctrip.com International Ltd. (NASDAQ: CTRP)

InvestorPlace.com “Top 5 Stocks for January” by Louis Navellier

Amazon.com Inc. (NASDAQ: AMZN)
AmBev (NYSE: ABV)
Baidu, Inc. (NASDAQ: BIDU)
Cognizant Technology (NASDAQ: CTSH)
Marvell Technology Group (NASDAQ: MRVL)

TheStreet.Com “Top Tech Stocks for 2010″

Amazon.com Inc. (NASDAQ: AMZN)
Comcast Corp. (NASDAQ: CMCSA)
Microsoft Corporation (NASDAQ: MSFT)
Red Hat Inc. (NYSE: RHT)
Research-in-Motion Ltd. (NASDAQ: RIMM)
VMware, Inc. (NYSE: VMW)

TheStreet.com also has two dividend picks for 2010:

Kimberly-Clark (NYSE: KMB)
CenturyTel (NYSE: CTL)

The Street.com “5 Shippers to Watch in 2010″

DryShips, Inc. (NASDAQ: DRYS)
Diana Shipping Inc. (NYSE: DSX)
Genco Shipping & Trading Ltd. (NYSE: GNK)
Navios Maritime Holdings Inc. (NYSE: NM)

Ten stocks for 2010, by James Altucher of TheStreet.com on AOL’s Daily Finance

Assured Guaranty (NYSE: AGO)
Wellcare Health Plans, Inc. (NYSE: WCG)
Potash Corp. of Saskatchewan (NYSE: POT)
Cash America International, Inc. (NYSE: CSH)
Becton Dickison & Co. (NYSE: BDX)
Hillenbrand, Inc. (NYSE: HI)
Telecom Corp. of New Zealand NYSE: (NZT)
STEC, Inc. (NASDAQ: STEC)
Alvarion Ltd. (NASDAQ: ALVR)
GlaxoSmithKline plc (NYSE: GSK)

MarketWatch.com “10 Turnarounds for 2010″ by Mark Hulbert:

Boston Scientific Corp. (NYSE: BSX)
The Brinks Co. (NYSE: BCO)
Citigroup Inc. (NYSE: C)
Eli Lilly & Co. (NYSE: LLY)
Integrated Device Technology (NASDAQ: IDTI)
KB Home (NYSE: KBH)
Level 3 Communications Inc. (NASDAQ: LVLT)
Molina Healthcare Inc. (NYSE: MOH)
The New York Times Company (NYSE: NYT)
Wendy’s/Arby’s Group (NYSE: WEN)

FORTUNE’s “Promising Companies for 2010″

Mastercard Inc. (NYSE: MA)
Amedisys Inc. (NASDAQ: AMED)
QUALCOMM Inc. (NASDAQ: QCOM)
PetroHawk Energy Corporation (NYSE: HK)
Baxter International (NYSE: BAX),
Quanta Services Inc. (NYSE: PWR)
Salesforce.com (NYSE: CRM)
American Tower Corp. (NYSE: AMT)
Vornado Realty Trust (NYSE: VNO)

Smart Money’s “Where to Invest in 2010″
The Recession Return picks:

GoldCorp. (NYSE: GG)
The Coca-Cola COmpany (NYSE: KO)
Procter & Gamble (NYSE: PG)
Abbott Laboratories (NYSE: ABT)

Plodding Along:

Strayer Education (NASDAQ: STRA)
Chevron Corp. (NYSE: CVX)
Hewlett-Packard (NYSE: HPQ)
Changyou.com Ltd. (NASDAQ: CYOU)

FAST TRACK PICKS:

Ingersoll-Rand (NYSE: IR)
Jos. A. Bank Clothiers (NASDAQ: JOSB)
BB&T Corp. (NYSE: BBT)
Kirby (NYSE: KEX)

MorningStar’s “10 Ultimate Stock-Pickers’ Stocks to Consider During 2010″:

Abbott Laboratories (NYSE: ABT)
Applied Materials Inc. (NASDAQ: AMAT)
Apollo Group (NASDAQ: APOL)
ExxonMobil Corp. (NYSE: XOM)
Genzyme Corp. (NASDAQ: GENZ)
ITT Education Services (NYSE: ESI)
Lowe’s Companies Inc. (NYSE: LOW)
Monsanto Co. (NYSE: MON)
Stryker Corp. (NYSE: SYK)
Thermo Fisher Scientific, Inc. (NYSE: TMO)

BloggingStocks.com has a best of 2010 picks list with some stocks as follows, from various writers, and these are a few picks from the first page:

American Superconductor Corp. (NASDAQ: AMSC)
China Advanced Construction Systems (NASDAQ: CADC)
Dollar Tree (NASDAQ: DLTR)
Kinder Morgan Energy Partners (NYSE: KMP)
EZchip Semiconductor (NASDAQ: EZCH)
National CineMedia (NASDAQ: NCMI)

247WallSt.com also created several important stock pick lists of its own for 2010:

Berkshire Hathaway Inc. (NYSE: BRK-A) holdings with the most upside from analyst target prices for 2010.
Will oil hit $100 in 2010?
Top 10 Brands for 2010
Will gold stay dead into 2010, or was the end of 2009 just the pause?
Here are 12 major M&A candidates for 2010, a dream list in a sense.
And then on the pessimistic side…. 10 brands that will disappear in 2010.

I would like to personally invite you to join in with the thousands of readers on our free daily email distribution list to hear about major market pundit stock picks, analyst upgrades and downgrades, day trader and active trader alerts, stock and market rumors, Buffett and guru investor news, M&A and IPOs, and more.

If you have other lists of Top Picks for 2010 you would like to see in an updated version of this over the weekend and/or next week and in 2010, feel free to email it to me! Happy New Year and best wishes on your success for investing and trading in 2010!

JON C. OGG
January 1, 2010

Posted in Active Trader, Analyst Calls, Banking, Banking & Finance, Biotech, Buffett, Calendar, China, Commodities, Commodities & Metals, Corporate Governance, Dividend, Dividends & Buybacks, Editor's Picks, Entertainment, Healthcare, Housing, Insider Activity, International Markets, Large Cap Stocks, Media, Mergers & Acquisitions, Mergers and Buy Outs, Oil & Gas, Press Digest, Shareholder Issues, Technology, Technology Companies, Trading Alert, Turnarounds, Value Investing Tagged: AAPL, BIDU, C, CMCSA, CVX, DRYS, GE, HPQ, KBH, LVLT, MRVL, POT

Friday’s Top Biotech and Medical Stocks

Douglas A. McIntyre — Sun, 04 Feb 2007 13:39:40 +0000

From BioHealth Investor

Biotechnology

SEATTLE GENETICS I [SGEN] +11.38%
IMMUNOGEN INC [IMGN] +8.86%
IDM PHARMA INC [IDMI] +8.58%
SUNESIS PHARMACEUTIC [SNSS] +8.55%
SANGAMO BIOSCIENCE [SGMO] +8.52%

Diagnostic Substances

NYMOX PHARM CORP [NYMX] +44.72%
VALERA PHARMACEUTICA [VLRX] +6.03%
HEALTHCARE TECH LTD [HCTL] +5.33%
OSTEOLOGIX INC [OLGX.OB] +5.26%
ICAGEN, INC. [ICGN] +3.78%

Drug Delivery

QUIGLEY CORP THE [QGLY] +3.88%
DELCATH SYSTEMS INC [DCTH] +3.20%
ELAN CP PLC ADR [ELN] +2.35%
HOSPIRA INC [HSP] +0.71%
BIOVAIL CORP [BVF] +0.48%

Drug Manufacturers

ACCESS PHARMACEUTICL [ACCP.OB] +72.00%
ALLOS THERAPEUTICS [ALTH] +9.84%
ALEXZA PHARMACEUTICA [ALXA] +8.09%
MARSHALL EDWARDS [MSHL] +3.62%
PHARMAXIS LTD ADR [PXSL] +3.41%

Medical Appliances & Equipment

SPECTRASCIENCE NEW [SCIE.OB] +22.64%
INTUITIVE SURG INC [ISRG] +17.57%
TRIMEDYNE INC [TMED.OB] +8.55%
VOLCANO CORPORATION [VOLC] +8.05%
REGENERATION TECH [RTIX] +6.78%

Medical Instruments & Supplies

HEMOSENSE INC. [HEM] +12.58% $0
EV3 INC. [EVVV] +12.20% $0
ROCHESTER MEDICAL [ROCM] +11.45% $56.7 M
ATRICURE, INC. [ATRC] +11.45% $8.9 M
MILESTONE SCIENTIFIC [MLSS.OB] +7.89%

Medical Laboratories & Research

BIO-IMAGING TECH [BITI] +4.99%
MEDASORB TECHNOLOGS [MSBT.OB] +4.17%
ALLIANCE IMAGING INC [AIQ] +1.84%
ARRAY BIOPHARMA IN [ARRY] +1.02%
PHARM PROD DEV [PPDI] +0.98%

http://www.biohealthinvestor.com/

Pre-Market Stock Notes (JAN 29, 2007)

Douglas A. McIntyre — Mon, 29 Jan 2007 08:27:49 +0000

(ADBE) Adobe launched new photo editor product.
(AH) Armor Holdings wins $44M army tank component order.
(ATRS) Altiris being acquired for $33 per share in Cash by Symantec.
(BMY) Bristol-Myers may be in merger talks with Sanofi-Aventis according to French reports.
(BOW) Bowater is merging with Abitibi-Consolidated (ABY) in merger of equals.
(BRCM) Broadcom was ruled in favor of in patent case from Qualcomm; ruling says they didn’t infringe patents.
(C) Citigroup is acquiring Egg Banking from Prudential for about $1.1+ Billion in UK.
(CHINA) CDC Corp is pre-installing its proprietary software in Nokia phones sold in China.
(CMI) Cummins $3.75 EPS vs $3.77e, butraised 2007 guidance.
(CMTL) Comtech wins $9.5M tracking system order from US Army.
(DALRQ) Delta may get $1B more from US Air.
(DNA) Genentech issued ‘Dear Doctor’ letter about increased stroke risk for Lucentis eye treatment.
(DRRX) Durect signed manufacturing pact with Hospira.
(EEEE) Educate being acquired by management group and Sterling/Citigroup private equity group for $8.00 per share.
(EOP) Equity Office was given a recommendation by ISS proxy service to accept the $54 Blackstone bid.
(FRC) First Republic will be acquired by Merrill Lynch for $55 per share.
(GOOG) Google will begin paying for some YouTube video content.
(GYMB) Gymboree announced a $50M share buyback plan.
(HLS) Healthsouth is selling its outpatient rehab division for $245 million in cash.
(HSY) Hershey announced confectionary joint venture in China with Lotte Confectionary Ltd. of Korea.
(IBM) IBM is acquiring private Softek Storage Solutions.
(IFX) Infineon down 0.4% after posting overseas profits.
(IRBT) iRobot won a $16.58M order for a 100 unit IED detector robots in Iraq.
(LAUR) Laureate Education is being acquired by CEO-led and private equity consortium for $60.50 per share in cash.
(MAT) Mattel $0.75 EPS vs $0.66e.
(MDCC) Molecular Devices gets $35.50 buyout from MDS.
(MOBI) Mobius Management Systems in expanded alliance with Microsoft.
(OSIP) OSI Pharm announces European regulatory approval of Tarceva for treatment of patients with pancreatic cancer.
(PD) Phelps Dodge $4.71 EPS vs $4.22e.
(QCOM) Qualcomm lost ruling; judge ruled that Broadcom is not infringing its patents.
(RMKR) Rainmaker acquired CAS Systems for some $2M at closing.
(SGP) Schering Plough $0.17 EPS vs $0.17e.
(SNSS) Sunesis Pharma showed positive Phase II cancer studies.
(SQNM) Sequenom and Lenetix Medical Screening Laboratory in research pact for rapid genetic screening and diagnostic testing.
(SURW) SureWest selling directory publishing unit to GateHouse Media (GHS) for $110M.
(SYY) Sysco $0.38 EPS vs $0.38e.
(TASR) Taser had another product liability suit dropped against it.
(TSN) Tyson $0.16 EPS vs $0.06e; unsure if comparable.
(TSO) Tesoro $2.28 EPS vs $1.92 estimate.
(VDM) Van der Moolen names new CFO.
(VZ) Verizon $0.62 EPS vs $0.61e.

Jon C.Ogg
January 29, 2007